Questions:: Exercise 4. Bioethical Dilemma of Gene Therapy

Exercise 4.
Bioethical Dilemma of Gene Therapy

Instructions: Read the article “Bubble kid" track success puts gene therapy back on track and
answer the questions that follow.
Questions:
1. What are the relevant facts of this case?
 Thus, kids with SCID were frequently known as 'bubble babies'. David Vetter from Texas
likewise had SCID and needed to live in a sterile domain for the greater part of his life
during the 1970/80s. He was referred to the media as the boy in the plastic bubble' and
wore a unique 'spacesuit' to shield him from infections.
 The concept of gene therapy is simple: insert a working gene into a person with a faulty
version, and its product should overcome the defect. But the reality is more
complicated; because you need something to integrate the gene into the patient’s DNA
and persuades the cells to read it. In other words, you need a vector. Viruses are the
obvious choice as they survive and spread by inserting their genes into the host’s
genome. (retroviruses to lentiviruses).
 Right now, quality treatment is being utilized to treat an entire scope of conditions.
Some exploration is just in the beginning periods with procedures despite everything
being tried in creature models, anyway the discoveries are promising.
2. What are some ethical questions or concerns raised in this case?
Because gene therapy involves making changes to the body’s set of basic instructions, it raises
many unique ethical concerns. These incorporate regard for privacy; autonomy; individual
wellbeing; duty regarding the genetic health of future kids; amplifying social wellbeing/limiting
genuine social damage; the conceptive freedom of people; hereditary equity; cost viability;
solidarity/common guide, and regard for contrast.
The ethical questions surrounding gene therapy include:

 How can “good” and “bad” uses of gene therapy be distinguished?
 Who decides which traits are normal and which constitute a disability or disorder?
 Will the high costs of gene therapy make it available only to the wealthy?
 Could the widespread use of gene therapy make society less accepting of people
who are different?
 Should people be allowed to use gene therapy to enhance basic human traits such
as height, intelligence, or athletic ability?
3. Who are the stakeholders in this situation? Who are affected by the decisions
made?
 The partners of the circumstance are specialists, scientists, and scholars since they
expected to chip away at a quality treatment that could effectively work at the patient.
They are liable for their jobs to discover a quality that ought to be good with a patient
yet it is more muddled than everybody might suspect since qualities can be erratic.
 Individuals who are influenced in this circumstance are the family and particularly the
patient that could usually occur to kids. The possibility of gene therapy is dubious. While
it could save people in the future in a family from having a specific hereditary issue, it
may influence the development of a baby unexpectedly or have long haul reactions that
are not yet known. Since individuals who might be influenced by the gene therapy are
not yet conceived, they can't pick whether to have the treatment since money can be a
thing to seek for a big treatment.
4. What values influence the decision of each group of stakeholders?
I think it’s their eagerness to help the patients to recover, the passion of helping other to
survive even if it’s too risky for them and their willingness to serve people and help people to
lengthen their lives a little bit more. Without willing members, sponsors and researchers would
be not able to do clinical preliminaries to propel science and improve clinical consideration.
Along these lines, it is fundamental to the clinical preliminaries venture that members be
regarded, that trust is kept up, and that information sharing has not become an obstruction to
expansive cooperation in clinical preliminaries. A few elements limit the capacity of partners to
accomplish this circumstance, including the absence of direct proof, the absence of a structure
to quantitatively evaluate hazard and advantage, and the absence of a formal expository way to
deal with survey vulnerability.

Questions:: Exercise 4. Bioethical Dilemma of Gene Therapy

Uploaded by

Copyright:

Available Formats

Questions:: Exercise 4. Bioethical Dilemma of Gene Therapy

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Questions:: Exercise 4. Bioethical Dilemma of Gene Therapy

Uploaded by

Copyright:

Available Formats

Exercise 4.

Bioethical Dilemma of Gene Therapy

1. What are the relevant facts of this case?

2. What are some ethical questions or concerns raised in this case?

The ethical questions surrounding gene therapy include:

4. What values influence the decision of each group of stakeholders?

You might also like